Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Alpharetta, Ga.-based company posted losses of -$5.6 million, or -28¢ per share, on sales of $5,000 for the 3 months ended Sept. 30. This is the 1st quarter that Clearside has reported revenue. Get the full story […]
MassDevice Earnings Roundup
Ocular Therapeutix plans FDA re-submission for Dextenza by end of year, earnings
Shares in Ocular Therapeutix (NSDQ:OCUL) surged this morning after the biopharmaceutical company met expectations on Wall Street with its 3rd-quarter results and announced it will re-submit its new drug application to the FDA for Dextenza, its post-surgical ocular pain reliever, by the end of the year. In July, the FDA denied approval for Ocular’s hydrogel plug designed […]
pSivida misses Q3 estimates, profits slide 47%
Shares in pSivida (NSDQ:PSDV) fell 6% today after the company missed expectations on Wall Street with its fiscal 1st-quarter results. The Watertown, Mass.-based company posted losses of -$7.2 million, or -21¢ per share, on sales of $277,000 for the 3 months ended Sept. 30, for a bottom-line loss of -47% on a -41% sales decline, compared […]
Haemonetics tops Q2 earnings forecast by 11c
Haemonetics (NYSE:HAE) yesterday posted fiscal 2nd-quarter numbers that topped expectations on Wall Street by more than a dime, despite flat sales growth, as the company executes a reorganization plan. The Braintree, Mass.-based blood management company posted profits of $19.8 million, or 38¢ per share, on sales of $220.3 million for the 3 months ended Oct. 1, […]
Catalent tops Q1 estimates, profits fall 61%
Shares in Catalent (NYSE:CTLT) rose yesterday after the drug-delivery company met expectations on Wall Street with its fiscal 1st-quarter results. The Somerset, N.J.-based company posted profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with […]
Third-quarter sales surge more than 50% for Mazor Robotics
Third-quarter sales for Mazor Robotics (NSDQ:MZOR) rose nearly 54% as the robot-assisted surgery company sold more guidance systems than during all of last year. Caesarea, Israel-based Mazor posted losses of -$5.2 million, or -11¢ per share, on sales of $7.6 million for the 3 months ended Sept. 30, keeping the bottom line flat compared with Q3 2015. […]
Flamel Technologies tops Q3 revenue, EPS estimate
Shares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the […]
Regeneron boosts profits, misses revenue in Q3
Shares in Regeneron (NSDQ:REGN) gained today after the biopharmaceutical company crushed earnings expectations on Wall Street with its 3rd quarter results. The Tarrytown, New York-based company posted profits of $264.8 million, or $2.27 per share, on sales of $1.22 billion for the 3 months ended September 30, for bottom-line growth of 26% on sales growth of 7.3% […]
Pulmatrix reports Q3 loss, revenue down 91%
Shares in Pulmatrix (NSDQ:PULM) rose slightly after the biotechnology company released its 3rd quarter results. The Lexington, Mass.-based company reeled in its losses 35% to $3.2 million compared to a $4.9 million loss in Q3 last year. Revenue fell 91% compared with the same period last year to $61,000 for the 3 months ended September 30, 2016. Losses per […]
Navidea reels in losses, boosts sales in Q3
Shares in Navidea (NYSE:NAVB) rose yesterday after the company met expectations on Wall Street with its 3rd quarter results. The Dublin, Ohio-based company pared its losses by -99.3% to -$59,377 on sales of $8.5 million for the 3 months ended Sept. 30, for sales growth of 112.5% compared with the same period last year. Earnings per share were […]
Becton Dickinson’s full-year profits soar 40%
Becton Dickinson (NYSE:BDX) shares gained nearly 4% today after the medical products giant posted fiscal 4th-quarter and full-year results that met or beat the consensus forecast on Wall Street. Franklin Lakes, N.J.-base BD posted profits of $19 million, or 9¢ per share, on sales of $3.23 billion for the 3 months ended Sept. 30, marking a […]